Drug Patent & Exclusivity Expiration Report - Week of Jan 27 2024 2025-01-27
This week, there are 10 drugs in the patent and exclusivity list. They are: - Myfembree by Sumitomo Pharma Switzerland, containing active ingredient Estradiol, Norethindrone Acetate, and Relugolix - Orgovyx by Sumitomo Pharma Switzerland, containing active ingredient Relugolix - Nulibry by Sentynl Therapeutics, containing active ingredient Fosdenopterin Hydrobromide - Delstrigo by Merck Sharp and Dohme, containing active ingredient Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate - Pifeltro by Merck Sharp and Dohme, containing active ingredient Doravirine - Geodon by Viatris Specialty, containing active ingredient Ziprasidone Hydrochloride - Reyvow by Eli Lilly, containing active ingredient Lasmiditan Succinate - Cabenuva Kit by ViiV Healthcare, containing active ingredient Cabotegravir and Rilpivirine - Vocabria by ViiV Healthcare, containing active ingredient Cabotegravir Sodium - Imbruvica by Pharmacyclics, containing active ingredient Ibrutinib
Read More